On July 29, 2026, Genenta Science S.p.A. held an Extraordinary Shareholders’ Meeting where the proposal to change its corporate name to Saentra Forge S.p.A. was deferred pending further evaluation of branding strategy and shareholder consultations; this revised proposal will be considered at a reconvened meeting on September 10 or 11, 2026. Shareholders approved a delegation granting the Board authority for five years to increase share capital by up to €300 million, issue up to 120 million new ordinary shares, and issue convertible bonds for strategic transactions or capital raises. Additionally, shareholders authorized a reverse stock split within a range of 1-for-10 to 1-for-20 to help maintain compliance with Nasdaq’s minimum bid price requirement, with the Board empowered to determine the specific ratio, effective date, and implementation details within twelve months. Genenta Science S.p.A. operates in the biotechnology industry, focusing on the development of therapies for rare diseases.

The Court of Milan revoked a preliminary order that had suspended the effectiveness of an amendment to the Company's corporate purpose in Article 4 of its bylaws. This ruling, notified to the Company on July 13, 2026, restores the amendment's effectiveness, citing the Company's strategic interest in avoiding a strategic impasse. The underlying civil action challenging the validity of the shareholder resolutions remains pending. Genenta Science S.p.A. is a biotechnology company focused on developing therapeutic solutions.

Genenta Science S.p.A. completed the acquisition of a majority equity ownership in Sòphia High Tech S.r.l. following receipt of authorization under Italian "Golden Power" legislation. At its June 29, 2026 Annual Ordinary Shareholders’ Meeting, the company appointed five directors for three-year terms with an aggregate annual compensation of €165,000 and authorized the purchase and disposal of treasury shares up to 30% of share capital for eighteen months. The Extraordinary Shareholders’ Meeting, which includes proposals for a corporate name change to Saentra Forge S.p.A., a share capital increase, and a reverse stock split, was adjourned to July 29-30, 2026, to allow for further shareholder engagement. The company operates in the biotechnology industry, focusing on life sciences and healthcare.

The Court of Milan issued an interim order regarding a legal challenge by minority shareholders. The Court denied a request to suspend the May 2, 2024, multiple voting rights mechanism, leaving it in effect. However, the Court suspended the efficacy of the October 29, 2025, resolution amending the Company's corporate purpose due to concerns regarding its breadth. Genenta Science S.p.A. is a biotechnology company focused on developing advanced therapeutic solutions.